Author: Tsai, Shih-Chang; Lu, Chi-Cheng; Bau, Da-Tian; Chiu, Yu-Jen; Yen, Yu-Ting; Hsu, Yuan-Man; Fu, Chih-Wei; Kuo, Sheng-Chu; Lo, Yu-Shiang; Chiu, Hong-Yi; Juan, Yu-Ning; Tsai, Fuu-Jen; Yang, Jai-Sing
Title: Approaches towards fighting the COVID-19 pandemic (Review) Cord-id: fftici40 Document date: 2020_11_20
ID: fftici40
Snippet: The coronavirus disease 2019 (COVID-19) outbreak, which has caused >46 millions confirmed infections and >1.2 million coronavirus related deaths, is one of the most devastating worldwide crises in recent years. Infection with COVID-19 results in a fever, dry cough, general fatigue, respiratory symptoms, diarrhoea and a sore throat, similar to those of acute respiratory distress syndrome. The causative agent of COVID-19, SARS-CoV-2, is a novel coronavirus strain. To date, remdesivir has been gran
Document: The coronavirus disease 2019 (COVID-19) outbreak, which has caused >46 millions confirmed infections and >1.2 million coronavirus related deaths, is one of the most devastating worldwide crises in recent years. Infection with COVID-19 results in a fever, dry cough, general fatigue, respiratory symptoms, diarrhoea and a sore throat, similar to those of acute respiratory distress syndrome. The causative agent of COVID-19, SARS-CoV-2, is a novel coronavirus strain. To date, remdesivir has been granted emergency use authorization for use in the management of infection. Additionally, several efficient diagnostic tools are being actively developed, and novel drugs and vaccines are being evaluated for their efficacy as therapeutic agents against COVID-19, or in the prevention of infection. The present review highlights the prevalent clinical manifestations of COVID-19, characterizes the SARS-CoV-2 viral genome sequence and life cycle, highlights the optimal methods for preventing viral transmission, and discusses possible molecular pharmacological mechanisms and approaches in the development of anti-SARS-CoV-2 therapeutic agents. In addition, the use of traditional Chinese medicines for management of COVID-19 is discussed. It is expected that novel anti-viral agents, vaccines or an effective combination therapy for treatment/management of SARS-CoV-2 infection and spread therapy will be developed and implemented in 2021, and we would like to extend our best regards to the frontline health workers across the world in their fight against COVID-19.
Search related documents:
Co phrase search for related documents- accurate rapid and acute ards respiratory distress syndrome: 1, 2, 3
- accurate rapid and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acid environment and acute sars cov respiratory syndrome coronavirus: 1
- acute ards respiratory distress syndrome and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- acute ards respiratory distress syndrome and adaptive innate immune response: 1, 2, 3, 4, 5, 6, 7
- acute ards respiratory distress syndrome and addition type: 1
- acute ards respiratory distress syndrome and admission lymphopenia: 1, 2
- acute sars cov respiratory syndrome coronavirus and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute sars cov respiratory syndrome coronavirus and adaptive innate immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- acute sars cov respiratory syndrome coronavirus and addition type: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute sars cov respiratory syndrome coronavirus and adenosine monophosphate: 1, 2
- acute sars cov respiratory syndrome coronavirus and admission lymphopenia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- adaptive innate and addition type: 1, 2, 3
- adaptive innate and adenosine monophosphate: 1
- adaptive innate and admission lymphopenia: 1, 2
- adaptive innate immune response and addition type: 1
Co phrase search for related documents, hyperlinks ordered by date